O. Проблемы терапевтической оценки ПОФ

Auerbach AD, Landefeld CS, Shojania KG. The tension between needing to improve care and knowing how to do it. N Engl J Med 357: 608-613, 2007

Hellman S, Hellman DS. Of mice but not men: problems of the randomized clinical trial. New Engl J Med 324: 1585-1589, 1991

Kaplan FS, Glaser DL, Pignolo RJ, Shore EM. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther 7: 705-712, 2007

Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby R, Kitterman JA, Groppe J, Shore EM. Fibrodysplasia ossificans progressiva (ПОФ). Best Practice & Research – Clinical Rheumatology 22: 191-205, 2008

Miller FG, Rosenstein DL. The therapeutic orientation to clinical trials. N Engl J Med 348: 1383-1386, 2003

Passamani E. Clinical trials - are they ethical? New Engl J Med 324: 1589-1591, 1991

Rosenstirn J. A contribution to the study of myositis ossificans progressiva. Ann Surg 68: 485-520, 591-637, 1918

Stephens T, Brynner R: Dark Remedy. The Impact of Thalidomide And Its Revival as a Vital Medicine. Perseus Books, 208 pages, 2001

Yu PB, Hong CC, Sachidanandan C, Babitt JL. Dong DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibitors КМГП signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41, 2008

II. ПАТОЛОГИЧЕСКИЕ И ПАТОФИЗИОЛОГИЧЕСКИЕ ОСНОВЫ МЕТОДОВ СИМПТОМАТИЧЕСКОГО ЛЕЧЕНИЯ ПОФ

Introduction

Glaser DL, Kaplan FS. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3: 243-250. 2005

Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby R, Kitterman JA, Groppe J, Shore EM. Fibrodysplasia ossificans progressiva (ПОФ). Best Practice & Research – Clinical Rheumatology 22: 191-205, 2008

B. Corticosteroids

Janoff HB, Zasloff MA, Kaplan FS. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg 114: 599-604, 1996

Rhen T & Cidlowski JA. Anti-inflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 353: 1711-1723, 2005

Staa TPV, Cooper C, Leufkens HGM, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18: 913-918, 2003

C. Ингибиторы мастоцитов

Gannon FH, Glaser D, Caron R, Thompson LDR, Shore EM, Kaplan FS. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 32: 842-848, 2001

Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 346:175-179, 2002

Simmons FER. Advances in H₁ –Antihistamines. N Engl J Med 351:2203-2217, 2004